Therefore, a decrease in YAP1/TAZ and an increase in CRB3 expression in the MS patients were expected, although no studies had been performed to investigate the expression of the core components of the Hippo pathway in MS. This evidence concerns the gene CRB3 and myeloid sarcoma.